메뉴 건너뛰기




Volumn 14, Issue 10, 2013, Pages 953-961

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): A randomised, double-blind phase 3 non-inferiority trial

(32)  Shi, Yuankai a,b   Zhang, Li c,f   Liu, Xiaoqing d   Zhou, Caicun e   Zhang, Shucai g   Wang, Dong h   Li, Qiang i   Qin, Shukui j   Hu, Chunhong k   Zhang, Yiping l   Chen, Jianhua m   Cheng, Ying n   Feng, Jifeng o   Zhang, Helong p   Song, Yong r   Wu, Yi Long s   Xu, Nong t   Zhou, Jianying t   Luo, Rongcheng u   Bai, Chunxue v   more..


Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; ICOTINIB; PLACEBO; PLATINUM COMPLEX; UNCLASSIFIED DRUG;

EID: 84883050731     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70355-3     Document Type: Article
Times cited : (413)

References (28)
  • 2
    • 22044445517 scopus 로고    scopus 로고
    • Erlotinib in previously treated non-small-cell lung cancer
    • Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
    • (2005) N Engl J Med , vol.353 , pp. 123-132
    • Shepherd, F.A.1    Rodrigues Pereira, J.2    Ciuleanu, T.3
  • 3
    • 56249109644 scopus 로고    scopus 로고
    • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
    • Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
    • (2008) Lancet , vol.372 , pp. 1809-1818
    • Kim, E.S.1    Hirsh, V.2    Mok, T.3
  • 4
    • 2342471392 scopus 로고    scopus 로고
    • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    • Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
    • (2004) N Engl J Med , vol.350 , pp. 2129-2139
    • Lynch, T.J.1    Bell, D.W.2    Sordella, R.3
  • 5
    • 4444344330 scopus 로고    scopus 로고
    • EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
    • Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101:13306-13311.
    • (2004) Proc Natl Acad Sci USA , vol.101 , pp. 13306-13311
    • Pao, W.1    Miller, V.2    Zakowski, M.3
  • 6
    • 84857502654 scopus 로고    scopus 로고
    • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
    • on behalf of the Spanish Lung Cancer Group in collaboration with the Groupe Français de Pneumo-Cancérologie, the Associazione Italiana Oncologia Toracicathe Associazione Italiana Oncologia Toracica
    • Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246. on behalf of the Spanish Lung Cancer Group in collaboration with the Groupe Français de Pneumo-Cancérologie, the Associazione Italiana Oncologia Toracicathe Associazione Italiana Oncologia Toracica.
    • (2012) Lancet Oncol , vol.13 , pp. 239-246
    • Rosell, R.1    Carcereny, E.2    Gervais, R.3
  • 7
    • 20044364940 scopus 로고    scopus 로고
    • Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
    • Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97:339-346.
    • (2005) J Natl Cancer Inst , vol.97 , pp. 339-346
    • Shigematsu, H.1    Lin, L.2    Takahashi, T.3
  • 8
    • 84867036676 scopus 로고    scopus 로고
    • Molecular epidemiological prospective study of EGFR mutations from Asian patients (pts) with advanced lung adenocarcinoma (PIONEER)
    • (abstr).
    • Yang PC, Shi Y, Au JS, et al. Molecular epidemiological prospective study of EGFR mutations from Asian patients (pts) with advanced lung adenocarcinoma (PIONEER). Proc Am Soc Clin Oncol 2012, 30(suppl):1534. (abstr).
    • (2012) Proc Am Soc Clin Oncol , vol.30 , Issue.SUPPL. , pp. 1534
    • Yang, P.C.1    Shi, Y.2    Au, J.S.3
  • 9
    • 65349161510 scopus 로고    scopus 로고
    • EGFR testing in lung cancer is ready for prime time
    • Hirsch FR, Bunn PA EGFR testing in lung cancer is ready for prime time. Lancet Oncol 2009, 10:432-433.
    • (2009) Lancet Oncol , vol.10 , pp. 432-433
    • Hirsch, F.R.1    Bunn, P.A.2
  • 10
    • 84859435053 scopus 로고    scopus 로고
    • Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies
    • Tan F, Shen X, Wang D, et al. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer 2012, 76:177-182.
    • (2012) Lung Cancer , vol.76 , pp. 177-182
    • Tan, F.1    Shen, X.2    Wang, D.3
  • 11
    • 79960035905 scopus 로고    scopus 로고
    • Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors
    • Zhao Q, Shentu J, Xu N, et al. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer 2011, 73:195-202.
    • (2011) Lung Cancer , vol.73 , pp. 195-202
    • Zhao, Q.1    Shentu, J.2    Xu, N.3
  • 12
    • 79960034992 scopus 로고    scopus 로고
    • Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer
    • Wang H, Zhang L, Wang Y, et al. Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer. Chin Med J (Engl) 2011, 124:1933-1938.
    • (2011) Chin Med J (Engl) , vol.124 , pp. 1933-1938
    • Wang, H.1    Zhang, L.2    Wang, Y.3
  • 13
    • 77955836641 scopus 로고    scopus 로고
    • Pharmocology and clinical evaluation of icotinib hydrochloride
    • (in Chinese).
    • Tan F, Zhang L, Zhao Q, et al. Pharmocology and clinical evaluation of icotinib hydrochloride. Chin J New Drugs 2009, 18:1-4. (in Chinese).
    • (2009) Chin J New Drugs , vol.18 , pp. 1-4
    • Tan, F.1    Zhang, L.2    Zhao, Q.3
  • 14
    • 80052794272 scopus 로고    scopus 로고
    • Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry
    • Liu D, Jiang J, Zhang L, Tan F, Wang Y, Hu P Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry. Rapid Commun Mass Spectrom 2011, 25:2131-2140.
    • (2011) Rapid Commun Mass Spectrom , vol.25 , pp. 2131-2140
    • Liu, D.1    Jiang, J.2    Zhang, L.3    Tan, F.4    Wang, Y.5    Hu, P.6
  • 15
    • 0036569870 scopus 로고    scopus 로고
    • ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial
    • Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002, 20:2240-2250.
    • (2002) J Clin Oncol , vol.20 , pp. 2240-2250
    • Ranson, M.1    Hammond, L.A.2    Ferry, D.3
  • 16
    • 0029042825 scopus 로고
    • Reliability and validity of the functional assessment of cancer therapy-lung (FACT-L) quality of life instrument
    • Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P Reliability and validity of the functional assessment of cancer therapy-lung (FACT-L) quality of life instrument. Lung Cancer 1995, 12:199-220.
    • (1995) Lung Cancer , vol.12 , pp. 199-220
    • Cella, D.F.1    Bonomi, A.E.2    Lloyd, S.R.3    Tulsky, D.S.4    Kaplan, E.5    Bonomi, P.6
  • 17
    • 10744228140 scopus 로고    scopus 로고
    • CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment
    • Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181.
    • (2003) Semin Radiat Oncol , vol.13 , pp. 176-181
    • Trotti, A.1    Colevas, A.D.2    Setser, A.3
  • 18
    • 33645302908 scopus 로고    scopus 로고
    • A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer
    • Park K, Goto K A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin 2006, 22:561-573.
    • (2006) Curr Med Res Opin , vol.22 , pp. 561-573
    • Park, K.1    Goto, K.2
  • 19
    • 0037472909 scopus 로고    scopus 로고
    • Design and analysis of non-inferiority mortality trials in oncology
    • Rothmann M, Li N, Chen G, Chi GY, Temple P, Tsou HH Design and analysis of non-inferiority mortality trials in oncology. Stat Med 2003, 22:239-264.
    • (2003) Stat Med , vol.22 , pp. 239-264
    • Rothmann, M.1    Li, N.2    Chen, G.3    Chi, G.Y.4    Temple, P.5    Tsou, H.H.6
  • 20
    • 83555166254 scopus 로고    scopus 로고
    • Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
    • Kim ST, Uhm JE, Lee J, et al. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer 2012, 75:82-88.
    • (2012) Lung Cancer , vol.75 , pp. 82-88
    • Kim, S.T.1    Uhm, J.E.2    Lee, J.3
  • 21
    • 77953980894 scopus 로고    scopus 로고
    • Comparison of gefitinib versus erlotinib in patients with non-small cell lung cancer who failed previous chemotherapy
    • Kim ST, Lee J, Kim JH, et al. Comparison of gefitinib versus erlotinib in patients with non-small cell lung cancer who failed previous chemotherapy. Cancer 2010, 116:3025-3033.
    • (2010) Cancer , vol.116 , pp. 3025-3033
    • Kim, S.T.1    Lee, J.2    Kim, J.H.3
  • 22
    • 79960034992 scopus 로고    scopus 로고
    • Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer
    • Wang H-P, Zhang L, Wang Y-X, et al. Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer. Chin Med J (Engl) 2011, 124:1933-1938.
    • (2011) Chin Med J (Engl) , vol.124 , pp. 1933-1938
    • Wang, H.-P.1    Zhang, L.2    Wang, Y.-X.3
  • 23
    • 84883051278 scopus 로고    scopus 로고
    • Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study
    • (abstr).
    • Tan F, Gu A, Zhang Y, et al. Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study. Proc Am Soc Clin Oncol 2013, 31(suppl):19161. (abstr).
    • (2013) Proc Am Soc Clin Oncol , vol.31 , Issue.SUPPL. , pp. 19161
    • Tan, F.1    Gu, A.2    Zhang, Y.3
  • 24
    • 76749154617 scopus 로고    scopus 로고
    • Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy
    • Lee DH, Park K, Kim JH, et al. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010, 16:1307-1314.
    • (2010) Clin Cancer Res , vol.16 , pp. 1307-1314
    • Lee, D.H.1    Park, K.2    Kim, J.H.3
  • 25
    • 33746933434 scopus 로고    scopus 로고
    • Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
    • Jänne PA, Johnson BE Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2006, 12:4416-4420.
    • (2006) Clin Cancer Res , vol.12 , pp. 4416-4420
    • Jänne, P.A.1    Johnson, B.E.2
  • 26
    • 52049090365 scopus 로고    scopus 로고
    • Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR21
    • Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR21. J Clin Oncol 2008, 26:4268-4275.
    • (2008) J Clin Oncol , vol.26 , pp. 4268-4275
    • Zhu, C.Q.1    da Cunha Santos, G.2    Ding, K.3
  • 27
    • 33750962024 scopus 로고    scopus 로고
    • Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
    • Hirsch FR, Varella-Garcia M, Bunn PA, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006, 24:5034-5042.
    • (2006) J Clin Oncol , vol.24 , pp. 5034-5042
    • Hirsch, F.R.1    Varella-Garcia, M.2    Bunn, P.A.3
  • 28
    • 84922687467 scopus 로고    scopus 로고
    • Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified
    • (in Chinese).
    • Song Z, Yu X, Cai J, et al. Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified. Zhongguo Fei Ai Za Zhi 2013, 16:138-143. (in Chinese).
    • (2013) Zhongguo Fei Ai Za Zhi , vol.16 , pp. 138-143
    • Song, Z.1    Yu, X.2    Cai, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.